Latest From Vericel Corp.
Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.
Following the acquisition of cell therapy assets from Sanofi, which Sanofi had secured in its purchase of Genzyme, Aastrom Biosciences changed its name to Vericel, doubled down in cell therapy and relocated to Massachusetts. Since then it has seen its revenues grow 12% per year from just under $43 million in 2013 to just under $64 million in 2017. The target for 2020: drive revenues north of $100 million.
Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad cross-section of biopharma insiders and observers about the deal-making environment – featured here are big pharma and industry experts.
Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Wound Healing & Tissue Repair
- Aastrom Biosciences Inc.
- North America
- Parent & Subsidiaries
- Vericel Corp.
- Senior Management
Dominick Colangelo, Pres. & CEO
Gerard Michel, VP, Corp. Dev. & CFO
Daniel Orlando, COO
Jonathan Hopper, CMO
- Contact Info
Phone: (617) 588-5555
64 Sidney St.
Cambridge, MA 02139
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.